SlideShare a Scribd company logo
MYOCARDIAL STUNNING AND
HIBERNATION
Dr Binjo J Vazhappilly.
SR , Cardiology Dept.
Calicut Medical College
Stunning
• Definition :
Prolonged and fully reversible dysfunction of
the ischemic heart that persists despite the
normalization of blood flow.
• 1st described by Heyndrickx et al in 1975 in
conscious dogs undergoing brief coronary
occlusions.
• In that study regional contractile dysfunction
lasted for 6 hrs following 5 min and > 24 hrs
following 15 min of ischemia.
Features of stunning
• Normal perfusion.
• Depressed myocardial function.
• Dissociation of usual relationship between
subendocardial flow and function.
• Reversible .
• Function improves with inotropic agents.
Brief total occlusion
Prolonged partial occlusion
• Stunning occurs in a wide variety of settings that
differ from one another in several aspects
• At experimental level it can occur during
1. Single , completely reversible episode of
regional ischemia (< 20 min )
2. Multiple, completely reversible episodes of
regional ischemia
3. Partly reversible plus partly irreversible
ischemia in vivo ( > 20 min & < 3 hrs)
4. After global ischemia in vitro (isolated heart
preparations)
5. After global ischemia in vivo (cardioplegic arrest)
6. After exercise-induced ischemia
Clinical Relevance
• In the clinical setting stunning can occur
1. Brief period of total coronary occlusion:
pts with angina due to spasm
2. Global ischemia after cardiopulmonary bypass.
3. In combination : Subendocardium is infarcted and
overlying subepicardium reversibly injured in MI
4. Following exercise in presence of a flow limiting
stenosis
5. Ischemic bout that is induced by PCI
Mechanisms of Stunning
• There is no unified view of pathogenesis of stunning
• Most plausible hypotheses are
Oxyradical hypothesis : oxidant stress secondary
to the generation of ROS.
Calcium hypothesis : results from disturbance of
cellular calcium homeostasis.
Oxyradical Hypothesis
• Role of ROS in pathogenesis of stunning is proven
• Its role in all settings of stunning is unclear
• ROS-mediated injury responsible for stunning occurs
in initial moments of reperfusion
• Antioxidant therapies alleviate stunning whether
begun before ischemia or just prior to reperfusion
• But ineffective when begun after reperfusion
• None of the antioxidant therapies completely
prevented myocardial stunning
Calcium hypothesis
• Transient Ca2+ overload activates Ca2+-dependent
proteases which degrades and induces covalent
modifications of myofilaments.
• It results in ↓ responsiveness to Ca2+, manifested by
a decrease in maximal force of contraction.
Myocardial Hibernation
• Term hibernation is borrowed from zoology and
implies an adaptive reduction of energy expenditure
through reduced activity in situation of reduced
energy supply.
• In CAD myocardial hibernation refers to adaptive
reduction of myocardial contractile function in
response to reduction of myocardial blood flow.
• Diamond et al. in 1978 1st used the word
hibernation in ischemic dog myocardium.
• Its importance was recognized by Rahimtoola in early
1980s.
Mechanisms of hibernation
• Smart heart hypothesis :
Myocardial metabolism and function are reduced to
match concomitant reduction in coronary blood flow
which prevents necrosis.
• Repetitive stunning hypothesis:
Repetitive episodes of ischemia results in
sustained depression of contractile function.
• Genomics of Survival
Maintained viability in hibernation suggests
possibility of genomic adaptation.
Major survival genes (antiapoptotic, cytoprotective
& growth-promoting genes) and their
corresponding proteins are up regulated in
hibernating myocardium.
Natural history of hibernation
Histological Features
• Myolysis
• Glycogen accumulation
• Increased interstitial fibrosis
Clinical Relevance
• 20 to 50 % of pts with chronic ischemic LV
dysfunction have significant amount of viable
hibernating myocardium.
• They improve with revascularization.
ASSESSMENT OF MYOCARDIAL
VIABILITY
• ECG : gives little information.
• Dobutamine stress echocardiography.
• SPECT with thallium-201 or technetium-99 m.
• PET
• MRI
Characteristics of dysfunctional but
viable myocardium
• ECG
No clear correlation between Q waves on ECG and
presence of viability.
Pts with preserved QT dispersion are likely to have
viable myocardium.
Pts with high QT dispersion have predominantly
non-viable scar tissue.
Dobutamine Stress Echocardiography
• Hypokinetic or akinetic regions improving during low
dose dobutamine infusion (5–10 µg/kg/min) is
indicative of viable tissue.
• At higher doses (upto 40 µg/kg/min plus atropine)
wall motion may improve or diminish, reflecting
inducible ischemia.
• Biphasic response is highly predictive of recovery of
function after revascularization.
Stress Echo Interpretation
Interpretation Rest /
Baseline
Low dose stress Peak & post
stress
Normal Normal Normal Hyper dynamic
Ischemic Normal Normal / severe
ischemia – new
RWMA
Decreased
Scar WMA No change No change
Hibernating WMA Improved Worsens
Stunned WMA Improved Improved
• Advantage of Echo based techniques
Safety , low cost , widespread availability of
equipment .
• Disadvantage
Spatial resolution is relatively low.
High interobserver variability.
Diagnostic accuracy is reduced in pts with poor
acoustic window.
SPECT
• Thallium-201
Early uptake is proportional to regional blood
flow & delayed uptake indicates preserved
Na+ K+ pump and an intact cell membrane.
Defects on initial images that improve later
are viable.
• Technetium 99
lipophilic molecules and their intracellular
retention requires intact mitochondrial function.
Gating allow simultaneous assessment of
myocardial perfusion & contractile function.
• SPECT has higher sensitivity & lower specificity
than techniques based on contractile reserve.
PET
• Glucose utilization is evaluated with FDG and
regional perfusion assessed with N13-ammonia,
rubidium-82, or O15- labeled water.
• A normal perfusion and FDG uptake or reduced
perfusion with enhanced FDG uptake indicates viable
myocardium.
• Concordant reduction in FDG uptake and myocardial
perfusion is indicative of scar tissue.
• PET is regarded as gold standard for viability
assessment.
Hibernation in LAD occlusion
FDG SPECT
Magnetic resonance imaging
• Three techniques are being used:
1.Resting MRI to measure end diastolic wall
thickness.
2. Dobutamine MRI to evaluate contractile reserve
3. Contrast enhanced MRI to detect extent
and transmurality of scar tissue.
• Resting MRI
End diastolic wall thickness < 6 mm represent
transmural scar.
• Dobutamine MRI
Evaluate contractile reserve.
Increased resolution of MRI avoid subjective
variation of echo.
Has sensitivity of 89% & specificity of 94% to predict
improvement after revascularization.
• Contrast enhanced MRI
Allows precise detection of scar tissue.
Extent & transmurality of scar can be assessed.
Can detect subendocardial scar.
Similar to FDG PET in detecting scar.
Accuracy of non-invasive techniques to
assess myocardial viability
Impact of Revascularization on LV Function
• Studies shows LV ejection fraction improves
significantly (ie ≥ 5%) after revascularization in 60%
of patients (range 38% to 88%).
• To predict 5% improvement in LVEF, at least 25% of
LV should be viable using DSE and ≈38% using
conventional nuclear medicine and PET.
• In dyskinetic and akinetic segments, absence of scar
or a transmural extension of scar of <25% have PPV
of 88% and NPV 89% for functional recovery.
Treatment and Survival Rates
• Meta-analysis that pooled data of 3,088 pts from 24
studies demonstrated improved survival after
revascularization in pts with hibernation.
• Revascularization resulted in 79.6% reduction in
mortality (16% vs 3.2%)
• In absence of hibernation, no significant difference
in mortality with revascularization (7.7% vs 6.2%).
Summary
• Stunning and hibernation are 2 causes for LV
dysfunction.
• Both conditions imply presence of viable
myocardium and are reversible.
References
• HURST’S THE HEART 13TH EDITION
• BRAUNWALD’S HEART DISEASE NINTH EDITION
• Medical and Cellular Implications of Stunning,
Hibernation, and Preconditioning :Circulation.
1998;97:1848-1867
• Stunning, Hibernation and Assessment of Myocardial
Viability : Circulation.2008;117:103-114
• Molecular and Cellular Mechanisms of Myocardial
Stunning :PHYSIOLOGICAL REVIEWS Vol. 79, No. 2,
April 1999
• Hibernating Myocardium : PHYSIOLOGICAL
REVIEWS Vol. 78, No. 4, October 1998
• Clinical assessment of myocardial hibernation
Heart 2005;91;111-117
THANK YOU

More Related Content

What's hot

Electrophysiologic basics,part1(lecture)
Electrophysiologic basics,part1(lecture)Electrophysiologic basics,part1(lecture)
Electrophysiologic basics,part1(lecture)
salah_atta
 
TRANS ESOPHAGEAL ECHOCARDIOGRAPHY
TRANS ESOPHAGEAL ECHOCARDIOGRAPHYTRANS ESOPHAGEAL ECHOCARDIOGRAPHY
TRANS ESOPHAGEAL ECHOCARDIOGRAPHY
Unnikrishnan Prathapadas
 
Cardiac risk stratification
Cardiac risk stratificationCardiac risk stratification
Cardiac risk stratification
Dr.S.N.Bhagirath ..
 
Renal protection during cardiac surgery iii
Renal protection during cardiac surgery iiiRenal protection during cardiac surgery iii
Renal protection during cardiac surgery iii
Ashraf Banoub
 
Anesthesia for coronary artery bypass grafting
Anesthesia for coronary artery bypass graftingAnesthesia for coronary artery bypass grafting
Anesthesia for coronary artery bypass grafting
aparna jayara
 
Valvular Heart Disease & Anaesthetic Implications
Valvular Heart Disease & Anaesthetic ImplicationsValvular Heart Disease & Anaesthetic Implications
Valvular Heart Disease & Anaesthetic Implications
Dr.Daber Pareed
 
Advances in haemodynamic monitoring
Advances in haemodynamic monitoringAdvances in haemodynamic monitoring
Advances in haemodynamic monitoring
Mohamed Abdulrazik
 
Minimaly invasive hemodynamic monitoring for hepatic patients
Minimaly invasive hemodynamic monitoring for hepatic patients Minimaly invasive hemodynamic monitoring for hepatic patients
Minimaly invasive hemodynamic monitoring for hepatic patients
Dr.Mahmoud Abbas
 
TEE VIEWS
TEE VIEWSTEE VIEWS
Perioperative cardiovascular assessment of patients undergoing noncardiac sur...
Perioperative cardiovascular assessment of patients undergoing noncardiac sur...Perioperative cardiovascular assessment of patients undergoing noncardiac sur...
Perioperative cardiovascular assessment of patients undergoing noncardiac sur...
kazi alam nowaz
 
Mechanical Circulatory Support.pptx
Mechanical Circulatory Support.pptxMechanical Circulatory Support.pptx
Mechanical Circulatory Support.pptx
LPS Institute of Cardiology Kanpur UP India
 
Perioperative cardiovascular evaluation for non cardiac surgery
Perioperative cardiovascular  evaluation for    non  cardiac surgeryPerioperative cardiovascular  evaluation for    non  cardiac surgery
Perioperative cardiovascular evaluation for non cardiac surgery
PROFESSOR DR. MD. TOUFIQUR RAHMAN
 
Mechanical circulatory support devices
Mechanical circulatory support devicesMechanical circulatory support devices
Mechanical circulatory support devices
RohitWalse2
 
Perioperative Cardiovascular Risk assessment
Perioperative Cardiovascular Risk assessmentPerioperative Cardiovascular Risk assessment
Perioperative Cardiovascular Risk assessment
Nizam Uddin
 
ECG approach to arrhythmias 2017
ECG approach to arrhythmias 2017ECG approach to arrhythmias 2017
ECG approach to arrhythmias 2017
Ashutosh Pakale
 
OPCAB
OPCABOPCAB
IImplantable Cardioverter Defibrillators (ICDs) - Dr Prithvi puwar
IImplantable Cardioverter Defibrillators (ICDs) - Dr Prithvi puwarIImplantable Cardioverter Defibrillators (ICDs) - Dr Prithvi puwar
IImplantable Cardioverter Defibrillators (ICDs) - Dr Prithvi puwar
Prithvi Puwar
 
Hocm mpuh
Hocm mpuhHocm mpuh
Hocm mpuh
Drnilesh Parikh
 
Extracoporeal Life Support presentation final
Extracoporeal Life Support presentation finalExtracoporeal Life Support presentation final
Extracoporeal Life Support presentation final
Ashraf Banoub
 
POCUS for Residents of Anesthesia and Critical care
POCUS for Residents of Anesthesia and Critical carePOCUS for Residents of Anesthesia and Critical care
POCUS for Residents of Anesthesia and Critical care
mansoor masjedi
 

What's hot (20)

Electrophysiologic basics,part1(lecture)
Electrophysiologic basics,part1(lecture)Electrophysiologic basics,part1(lecture)
Electrophysiologic basics,part1(lecture)
 
TRANS ESOPHAGEAL ECHOCARDIOGRAPHY
TRANS ESOPHAGEAL ECHOCARDIOGRAPHYTRANS ESOPHAGEAL ECHOCARDIOGRAPHY
TRANS ESOPHAGEAL ECHOCARDIOGRAPHY
 
Cardiac risk stratification
Cardiac risk stratificationCardiac risk stratification
Cardiac risk stratification
 
Renal protection during cardiac surgery iii
Renal protection during cardiac surgery iiiRenal protection during cardiac surgery iii
Renal protection during cardiac surgery iii
 
Anesthesia for coronary artery bypass grafting
Anesthesia for coronary artery bypass graftingAnesthesia for coronary artery bypass grafting
Anesthesia for coronary artery bypass grafting
 
Valvular Heart Disease & Anaesthetic Implications
Valvular Heart Disease & Anaesthetic ImplicationsValvular Heart Disease & Anaesthetic Implications
Valvular Heart Disease & Anaesthetic Implications
 
Advances in haemodynamic monitoring
Advances in haemodynamic monitoringAdvances in haemodynamic monitoring
Advances in haemodynamic monitoring
 
Minimaly invasive hemodynamic monitoring for hepatic patients
Minimaly invasive hemodynamic monitoring for hepatic patients Minimaly invasive hemodynamic monitoring for hepatic patients
Minimaly invasive hemodynamic monitoring for hepatic patients
 
TEE VIEWS
TEE VIEWSTEE VIEWS
TEE VIEWS
 
Perioperative cardiovascular assessment of patients undergoing noncardiac sur...
Perioperative cardiovascular assessment of patients undergoing noncardiac sur...Perioperative cardiovascular assessment of patients undergoing noncardiac sur...
Perioperative cardiovascular assessment of patients undergoing noncardiac sur...
 
Mechanical Circulatory Support.pptx
Mechanical Circulatory Support.pptxMechanical Circulatory Support.pptx
Mechanical Circulatory Support.pptx
 
Perioperative cardiovascular evaluation for non cardiac surgery
Perioperative cardiovascular  evaluation for    non  cardiac surgeryPerioperative cardiovascular  evaluation for    non  cardiac surgery
Perioperative cardiovascular evaluation for non cardiac surgery
 
Mechanical circulatory support devices
Mechanical circulatory support devicesMechanical circulatory support devices
Mechanical circulatory support devices
 
Perioperative Cardiovascular Risk assessment
Perioperative Cardiovascular Risk assessmentPerioperative Cardiovascular Risk assessment
Perioperative Cardiovascular Risk assessment
 
ECG approach to arrhythmias 2017
ECG approach to arrhythmias 2017ECG approach to arrhythmias 2017
ECG approach to arrhythmias 2017
 
OPCAB
OPCABOPCAB
OPCAB
 
IImplantable Cardioverter Defibrillators (ICDs) - Dr Prithvi puwar
IImplantable Cardioverter Defibrillators (ICDs) - Dr Prithvi puwarIImplantable Cardioverter Defibrillators (ICDs) - Dr Prithvi puwar
IImplantable Cardioverter Defibrillators (ICDs) - Dr Prithvi puwar
 
Hocm mpuh
Hocm mpuhHocm mpuh
Hocm mpuh
 
Extracoporeal Life Support presentation final
Extracoporeal Life Support presentation finalExtracoporeal Life Support presentation final
Extracoporeal Life Support presentation final
 
POCUS for Residents of Anesthesia and Critical care
POCUS for Residents of Anesthesia and Critical carePOCUS for Residents of Anesthesia and Critical care
POCUS for Residents of Anesthesia and Critical care
 

Similar to stunned myocardium PPT.pptx

Myocardial Viability Biplave.pptx
Myocardial Viability Biplave.pptxMyocardial Viability Biplave.pptx
Myocardial Viability Biplave.pptx
biplave karki
 
Viability assessment final new
Viability assessment final newViability assessment final new
Myocardial viability
Myocardial viabilityMyocardial viability
Myocardial viability
Raghuram Krishnan
 
Assessment of myocardial viability
Assessment of myocardial viabilityAssessment of myocardial viability
Assessment of myocardial viability
Ashish Golwara
 
Myocardial viability
Myocardial viability  Myocardial viability
Myocardial viability
Prithvi Puwar
 
Crt
CrtCrt
Stressechocardiography
StressechocardiographyStressechocardiography
Stressechocardiography
Senbeta
 
Stress echocardiography
Stress echocardiographyStress echocardiography
Stress echocardiography
Fuad Farooq
 
Crrt indications and modalities [autosaved]
Crrt indications and modalities [autosaved]Crrt indications and modalities [autosaved]
Crrt indications and modalities [autosaved]
FAARRAG
 
Anaethetic management of scoliotic patients
Anaethetic management of scoliotic patientsAnaethetic management of scoliotic patients
Anaethetic management of scoliotic patients
mohamed mohamed
 
Nuclear medicine for cardiothoracic surgeons
Nuclear medicine for cardiothoracic surgeonsNuclear medicine for cardiothoracic surgeons
Nuclear medicine for cardiothoracic surgeons
SrikanthK120
 
Dobutamine stress echocardiography
Dobutamine stress echocardiographyDobutamine stress echocardiography
Dobutamine stress echocardiography
Himanshu Rana
 
Anesthesia for Total Knee replacement 4-3-2017
Anesthesia for Total Knee replacement 4-3-2017Anesthesia for Total Knee replacement 4-3-2017
Anesthesia for Total Knee replacement 4-3-2017
Aftab Hussain
 
CRRT with Prismaflex slides renal replacement.pdf
CRRT with Prismaflex slides renal replacement.pdfCRRT with Prismaflex slides renal replacement.pdf
CRRT with Prismaflex slides renal replacement.pdf
chaser86
 
Renal replacement therapy AND HD P1.pptx
Renal replacement therapy AND HD P1.pptxRenal replacement therapy AND HD P1.pptx
Renal replacement therapy AND HD P1.pptx
OnkarKole3
 
The hibernating myocardium
The hibernating myocardiumThe hibernating myocardium
The hibernating myocardium
madhusiva03
 
Crrt in aki
Crrt in akiCrrt in aki
Crrt in aki
FarragBahbah
 
Assessment of myocardial viability
Assessment of myocardial viabilityAssessment of myocardial viability
Assessment of myocardial viability
Swapnil Garde
 
Inotropes and vasopressors.pptx
Inotropes and vasopressors.pptxInotropes and vasopressors.pptx
Inotropes and vasopressors.pptx
Mayurjaganiya1
 
ANS
ANSANS

Similar to stunned myocardium PPT.pptx (20)

Myocardial Viability Biplave.pptx
Myocardial Viability Biplave.pptxMyocardial Viability Biplave.pptx
Myocardial Viability Biplave.pptx
 
Viability assessment final new
Viability assessment final newViability assessment final new
Viability assessment final new
 
Myocardial viability
Myocardial viabilityMyocardial viability
Myocardial viability
 
Assessment of myocardial viability
Assessment of myocardial viabilityAssessment of myocardial viability
Assessment of myocardial viability
 
Myocardial viability
Myocardial viability  Myocardial viability
Myocardial viability
 
Crt
CrtCrt
Crt
 
Stressechocardiography
StressechocardiographyStressechocardiography
Stressechocardiography
 
Stress echocardiography
Stress echocardiographyStress echocardiography
Stress echocardiography
 
Crrt indications and modalities [autosaved]
Crrt indications and modalities [autosaved]Crrt indications and modalities [autosaved]
Crrt indications and modalities [autosaved]
 
Anaethetic management of scoliotic patients
Anaethetic management of scoliotic patientsAnaethetic management of scoliotic patients
Anaethetic management of scoliotic patients
 
Nuclear medicine for cardiothoracic surgeons
Nuclear medicine for cardiothoracic surgeonsNuclear medicine for cardiothoracic surgeons
Nuclear medicine for cardiothoracic surgeons
 
Dobutamine stress echocardiography
Dobutamine stress echocardiographyDobutamine stress echocardiography
Dobutamine stress echocardiography
 
Anesthesia for Total Knee replacement 4-3-2017
Anesthesia for Total Knee replacement 4-3-2017Anesthesia for Total Knee replacement 4-3-2017
Anesthesia for Total Knee replacement 4-3-2017
 
CRRT with Prismaflex slides renal replacement.pdf
CRRT with Prismaflex slides renal replacement.pdfCRRT with Prismaflex slides renal replacement.pdf
CRRT with Prismaflex slides renal replacement.pdf
 
Renal replacement therapy AND HD P1.pptx
Renal replacement therapy AND HD P1.pptxRenal replacement therapy AND HD P1.pptx
Renal replacement therapy AND HD P1.pptx
 
The hibernating myocardium
The hibernating myocardiumThe hibernating myocardium
The hibernating myocardium
 
Crrt in aki
Crrt in akiCrrt in aki
Crrt in aki
 
Assessment of myocardial viability
Assessment of myocardial viabilityAssessment of myocardial viability
Assessment of myocardial viability
 
Inotropes and vasopressors.pptx
Inotropes and vasopressors.pptxInotropes and vasopressors.pptx
Inotropes and vasopressors.pptx
 
ANS
ANSANS
ANS
 

More from AdelSALLAM4

SGLT2 HF CKD Presentation NYSCHP Maya Chilbert june 2022.pptx
SGLT2 HF CKD Presentation NYSCHP Maya Chilbert  june 2022.pptxSGLT2 HF CKD Presentation NYSCHP Maya Chilbert  june 2022.pptx
SGLT2 HF CKD Presentation NYSCHP Maya Chilbert june 2022.pptx
AdelSALLAM4
 
PARAGON ESC presentation 8-31-19 v5.0.pptx
PARAGON ESC presentation 8-31-19 v5.0.pptxPARAGON ESC presentation 8-31-19 v5.0.pptx
PARAGON ESC presentation 8-31-19 v5.0.pptx
AdelSALLAM4
 
ticagrelor FOR ACS PATIENT WITH CARDIOGENIC CSHOK Dr Adel.pptx
ticagrelor FOR ACS PATIENT WITH CARDIOGENIC CSHOK Dr Adel.pptxticagrelor FOR ACS PATIENT WITH CARDIOGENIC CSHOK Dr Adel.pptx
ticagrelor FOR ACS PATIENT WITH CARDIOGENIC CSHOK Dr Adel.pptx
AdelSALLAM4
 
Brilinta_STEMI_Promotional_Slides_Update_(1)[1].pptx
Brilinta_STEMI_Promotional_Slides_Update_(1)[1].pptxBrilinta_STEMI_Promotional_Slides_Update_(1)[1].pptx
Brilinta_STEMI_Promotional_Slides_Update_(1)[1].pptx
AdelSALLAM4
 
8a- Hypertension & Diabetes Case Studies.pptx
8a- Hypertension & Diabetes Case Studies.pptx8a- Hypertension & Diabetes Case Studies.pptx
8a- Hypertension & Diabetes Case Studies.pptx
AdelSALLAM4
 
evolution in dyslipidemia management final.pptx
evolution in dyslipidemia management final.pptxevolution in dyslipidemia management final.pptx
evolution in dyslipidemia management final.pptx
AdelSALLAM4
 
HF role ofentresto.pdf
HF role ofentresto.pdfHF role ofentresto.pdf
HF role ofentresto.pdf
AdelSALLAM4
 
hypertension final(1).ppt
hypertension final(1).ppthypertension final(1).ppt
hypertension final(1).ppt
AdelSALLAM4
 
ACCSAP8_PPT_HYPERTENSION_08032016.pptx
ACCSAP8_PPT_HYPERTENSION_08032016.pptxACCSAP8_PPT_HYPERTENSION_08032016.pptx
ACCSAP8_PPT_HYPERTENSION_08032016.pptx
AdelSALLAM4
 
BP_Control.ppt physology1.ppt
BP_Control.ppt physology1.pptBP_Control.ppt physology1.ppt
BP_Control.ppt physology1.ppt
AdelSALLAM4
 
BP_Control.ppt physology1.ppt
BP_Control.ppt physology1.pptBP_Control.ppt physology1.ppt
BP_Control.ppt physology1.ppt
AdelSALLAM4
 
landmarck trial in HF.pdf
landmarck trial in HF.pdflandmarck trial in HF.pdf
landmarck trial in HF.pdf
AdelSALLAM4
 
id_08133649_Cardiovasculardisease.pptx
id_08133649_Cardiovasculardisease.pptxid_08133649_Cardiovasculardisease.pptx
id_08133649_Cardiovasculardisease.pptx
AdelSALLAM4
 
ESC guidline 2020.pptx
ESC guidline 2020.pptxESC guidline 2020.pptx
ESC guidline 2020.pptx
AdelSALLAM4
 
NSTEMI MVD Promotional Slides Update (1).pptx
NSTEMI MVD Promotional Slides Update (1).pptxNSTEMI MVD Promotional Slides Update (1).pptx
NSTEMI MVD Promotional Slides Update (1).pptx
AdelSALLAM4
 
2021 Chest Pain Clinical Update FINAL 102821(1).pptx
2021 Chest Pain Clinical Update FINAL 102821(1).pptx2021 Chest Pain Clinical Update FINAL 102821(1).pptx
2021 Chest Pain Clinical Update FINAL 102821(1).pptx
AdelSALLAM4
 
KDIGO-2021-BP-Guideline-Speakers-Guide(1).pptx
KDIGO-2021-BP-Guideline-Speakers-Guide(1).pptxKDIGO-2021-BP-Guideline-Speakers-Guide(1).pptx
KDIGO-2021-BP-Guideline-Speakers-Guide(1).pptx
AdelSALLAM4
 
Management-of-CAD.ppt
Management-of-CAD.pptManagement-of-CAD.ppt
Management-of-CAD.ppt
AdelSALLAM4
 
The unmet needs of patients with heart failure meeting 17 Feb 2022.pptx
The unmet needs of patients with heart failure meeting  17 Feb 2022.pptxThe unmet needs of patients with heart failure meeting  17 Feb 2022.pptx
The unmet needs of patients with heart failure meeting 17 Feb 2022.pptx
AdelSALLAM4
 
The unmet needs of patients with heart failure meeting 17 Feb 2022.pptx
The unmet needs of patients with heart failure meeting  17 Feb 2022.pptxThe unmet needs of patients with heart failure meeting  17 Feb 2022.pptx
The unmet needs of patients with heart failure meeting 17 Feb 2022.pptx
AdelSALLAM4
 

More from AdelSALLAM4 (20)

SGLT2 HF CKD Presentation NYSCHP Maya Chilbert june 2022.pptx
SGLT2 HF CKD Presentation NYSCHP Maya Chilbert  june 2022.pptxSGLT2 HF CKD Presentation NYSCHP Maya Chilbert  june 2022.pptx
SGLT2 HF CKD Presentation NYSCHP Maya Chilbert june 2022.pptx
 
PARAGON ESC presentation 8-31-19 v5.0.pptx
PARAGON ESC presentation 8-31-19 v5.0.pptxPARAGON ESC presentation 8-31-19 v5.0.pptx
PARAGON ESC presentation 8-31-19 v5.0.pptx
 
ticagrelor FOR ACS PATIENT WITH CARDIOGENIC CSHOK Dr Adel.pptx
ticagrelor FOR ACS PATIENT WITH CARDIOGENIC CSHOK Dr Adel.pptxticagrelor FOR ACS PATIENT WITH CARDIOGENIC CSHOK Dr Adel.pptx
ticagrelor FOR ACS PATIENT WITH CARDIOGENIC CSHOK Dr Adel.pptx
 
Brilinta_STEMI_Promotional_Slides_Update_(1)[1].pptx
Brilinta_STEMI_Promotional_Slides_Update_(1)[1].pptxBrilinta_STEMI_Promotional_Slides_Update_(1)[1].pptx
Brilinta_STEMI_Promotional_Slides_Update_(1)[1].pptx
 
8a- Hypertension & Diabetes Case Studies.pptx
8a- Hypertension & Diabetes Case Studies.pptx8a- Hypertension & Diabetes Case Studies.pptx
8a- Hypertension & Diabetes Case Studies.pptx
 
evolution in dyslipidemia management final.pptx
evolution in dyslipidemia management final.pptxevolution in dyslipidemia management final.pptx
evolution in dyslipidemia management final.pptx
 
HF role ofentresto.pdf
HF role ofentresto.pdfHF role ofentresto.pdf
HF role ofentresto.pdf
 
hypertension final(1).ppt
hypertension final(1).ppthypertension final(1).ppt
hypertension final(1).ppt
 
ACCSAP8_PPT_HYPERTENSION_08032016.pptx
ACCSAP8_PPT_HYPERTENSION_08032016.pptxACCSAP8_PPT_HYPERTENSION_08032016.pptx
ACCSAP8_PPT_HYPERTENSION_08032016.pptx
 
BP_Control.ppt physology1.ppt
BP_Control.ppt physology1.pptBP_Control.ppt physology1.ppt
BP_Control.ppt physology1.ppt
 
BP_Control.ppt physology1.ppt
BP_Control.ppt physology1.pptBP_Control.ppt physology1.ppt
BP_Control.ppt physology1.ppt
 
landmarck trial in HF.pdf
landmarck trial in HF.pdflandmarck trial in HF.pdf
landmarck trial in HF.pdf
 
id_08133649_Cardiovasculardisease.pptx
id_08133649_Cardiovasculardisease.pptxid_08133649_Cardiovasculardisease.pptx
id_08133649_Cardiovasculardisease.pptx
 
ESC guidline 2020.pptx
ESC guidline 2020.pptxESC guidline 2020.pptx
ESC guidline 2020.pptx
 
NSTEMI MVD Promotional Slides Update (1).pptx
NSTEMI MVD Promotional Slides Update (1).pptxNSTEMI MVD Promotional Slides Update (1).pptx
NSTEMI MVD Promotional Slides Update (1).pptx
 
2021 Chest Pain Clinical Update FINAL 102821(1).pptx
2021 Chest Pain Clinical Update FINAL 102821(1).pptx2021 Chest Pain Clinical Update FINAL 102821(1).pptx
2021 Chest Pain Clinical Update FINAL 102821(1).pptx
 
KDIGO-2021-BP-Guideline-Speakers-Guide(1).pptx
KDIGO-2021-BP-Guideline-Speakers-Guide(1).pptxKDIGO-2021-BP-Guideline-Speakers-Guide(1).pptx
KDIGO-2021-BP-Guideline-Speakers-Guide(1).pptx
 
Management-of-CAD.ppt
Management-of-CAD.pptManagement-of-CAD.ppt
Management-of-CAD.ppt
 
The unmet needs of patients with heart failure meeting 17 Feb 2022.pptx
The unmet needs of patients with heart failure meeting  17 Feb 2022.pptxThe unmet needs of patients with heart failure meeting  17 Feb 2022.pptx
The unmet needs of patients with heart failure meeting 17 Feb 2022.pptx
 
The unmet needs of patients with heart failure meeting 17 Feb 2022.pptx
The unmet needs of patients with heart failure meeting  17 Feb 2022.pptxThe unmet needs of patients with heart failure meeting  17 Feb 2022.pptx
The unmet needs of patients with heart failure meeting 17 Feb 2022.pptx
 

Recently uploaded

RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
IreneSebastianRueco1
 
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat  Leveraging AI for Diversity, Equity, and InclusionExecutive Directors Chat  Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
TechSoup
 
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptxChapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
The History of Stoke Newington Street Names
The History of Stoke Newington Street NamesThe History of Stoke Newington Street Names
The History of Stoke Newington Street Names
History of Stoke Newington
 
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdfANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
Priyankaranawat4
 
DRUGS AND ITS classification slide share
DRUGS AND ITS classification slide shareDRUGS AND ITS classification slide share
DRUGS AND ITS classification slide share
taiba qazi
 
Hindi varnamala | hindi alphabet PPT.pdf
Hindi varnamala | hindi alphabet PPT.pdfHindi varnamala | hindi alphabet PPT.pdf
Hindi varnamala | hindi alphabet PPT.pdf
Dr. Mulla Adam Ali
 
How to Manage Your Lost Opportunities in Odoo 17 CRM
How to Manage Your Lost Opportunities in Odoo 17 CRMHow to Manage Your Lost Opportunities in Odoo 17 CRM
How to Manage Your Lost Opportunities in Odoo 17 CRM
Celine George
 
How to Build a Module in Odoo 17 Using the Scaffold Method
How to Build a Module in Odoo 17 Using the Scaffold MethodHow to Build a Module in Odoo 17 Using the Scaffold Method
How to Build a Module in Odoo 17 Using the Scaffold Method
Celine George
 
C1 Rubenstein AP HuG xxxxxxxxxxxxxx.pptx
C1 Rubenstein AP HuG xxxxxxxxxxxxxx.pptxC1 Rubenstein AP HuG xxxxxxxxxxxxxx.pptx
C1 Rubenstein AP HuG xxxxxxxxxxxxxx.pptx
mulvey2
 
How to Add Chatter in the odoo 17 ERP Module
How to Add Chatter in the odoo 17 ERP ModuleHow to Add Chatter in the odoo 17 ERP Module
How to Add Chatter in the odoo 17 ERP Module
Celine George
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...
National Information Standards Organization (NISO)
 
Digital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental DesignDigital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental Design
amberjdewit93
 
Types of Herbal Cosmetics its standardization.
Types of Herbal Cosmetics its standardization.Types of Herbal Cosmetics its standardization.
Types of Herbal Cosmetics its standardization.
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHatAzure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
Scholarhat
 
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
PECB
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
heathfieldcps1
 
Your Skill Boost Masterclass: Strategies for Effective Upskilling
Your Skill Boost Masterclass: Strategies for Effective UpskillingYour Skill Boost Masterclass: Strategies for Effective Upskilling
Your Skill Boost Masterclass: Strategies for Effective Upskilling
Excellence Foundation for South Sudan
 
A Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptxA Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptx
thanhdowork
 

Recently uploaded (20)

RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
 
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat  Leveraging AI for Diversity, Equity, and InclusionExecutive Directors Chat  Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
 
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptxChapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
 
The History of Stoke Newington Street Names
The History of Stoke Newington Street NamesThe History of Stoke Newington Street Names
The History of Stoke Newington Street Names
 
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdfANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
 
DRUGS AND ITS classification slide share
DRUGS AND ITS classification slide shareDRUGS AND ITS classification slide share
DRUGS AND ITS classification slide share
 
Hindi varnamala | hindi alphabet PPT.pdf
Hindi varnamala | hindi alphabet PPT.pdfHindi varnamala | hindi alphabet PPT.pdf
Hindi varnamala | hindi alphabet PPT.pdf
 
How to Manage Your Lost Opportunities in Odoo 17 CRM
How to Manage Your Lost Opportunities in Odoo 17 CRMHow to Manage Your Lost Opportunities in Odoo 17 CRM
How to Manage Your Lost Opportunities in Odoo 17 CRM
 
How to Build a Module in Odoo 17 Using the Scaffold Method
How to Build a Module in Odoo 17 Using the Scaffold MethodHow to Build a Module in Odoo 17 Using the Scaffold Method
How to Build a Module in Odoo 17 Using the Scaffold Method
 
C1 Rubenstein AP HuG xxxxxxxxxxxxxx.pptx
C1 Rubenstein AP HuG xxxxxxxxxxxxxx.pptxC1 Rubenstein AP HuG xxxxxxxxxxxxxx.pptx
C1 Rubenstein AP HuG xxxxxxxxxxxxxx.pptx
 
How to Add Chatter in the odoo 17 ERP Module
How to Add Chatter in the odoo 17 ERP ModuleHow to Add Chatter in the odoo 17 ERP Module
How to Add Chatter in the odoo 17 ERP Module
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...
 
Digital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental DesignDigital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental Design
 
Types of Herbal Cosmetics its standardization.
Types of Herbal Cosmetics its standardization.Types of Herbal Cosmetics its standardization.
Types of Herbal Cosmetics its standardization.
 
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHatAzure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
 
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
 
Your Skill Boost Masterclass: Strategies for Effective Upskilling
Your Skill Boost Masterclass: Strategies for Effective UpskillingYour Skill Boost Masterclass: Strategies for Effective Upskilling
Your Skill Boost Masterclass: Strategies for Effective Upskilling
 
A Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptxA Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptx
 

stunned myocardium PPT.pptx

  • 1. MYOCARDIAL STUNNING AND HIBERNATION Dr Binjo J Vazhappilly. SR , Cardiology Dept. Calicut Medical College
  • 2. Stunning • Definition : Prolonged and fully reversible dysfunction of the ischemic heart that persists despite the normalization of blood flow.
  • 3. • 1st described by Heyndrickx et al in 1975 in conscious dogs undergoing brief coronary occlusions. • In that study regional contractile dysfunction lasted for 6 hrs following 5 min and > 24 hrs following 15 min of ischemia.
  • 4. Features of stunning • Normal perfusion. • Depressed myocardial function. • Dissociation of usual relationship between subendocardial flow and function. • Reversible . • Function improves with inotropic agents.
  • 7. • Stunning occurs in a wide variety of settings that differ from one another in several aspects • At experimental level it can occur during 1. Single , completely reversible episode of regional ischemia (< 20 min ) 2. Multiple, completely reversible episodes of regional ischemia 3. Partly reversible plus partly irreversible ischemia in vivo ( > 20 min & < 3 hrs)
  • 8. 4. After global ischemia in vitro (isolated heart preparations) 5. After global ischemia in vivo (cardioplegic arrest) 6. After exercise-induced ischemia
  • 9. Clinical Relevance • In the clinical setting stunning can occur 1. Brief period of total coronary occlusion: pts with angina due to spasm 2. Global ischemia after cardiopulmonary bypass. 3. In combination : Subendocardium is infarcted and overlying subepicardium reversibly injured in MI 4. Following exercise in presence of a flow limiting stenosis 5. Ischemic bout that is induced by PCI
  • 10. Mechanisms of Stunning • There is no unified view of pathogenesis of stunning • Most plausible hypotheses are Oxyradical hypothesis : oxidant stress secondary to the generation of ROS. Calcium hypothesis : results from disturbance of cellular calcium homeostasis.
  • 11. Oxyradical Hypothesis • Role of ROS in pathogenesis of stunning is proven • Its role in all settings of stunning is unclear • ROS-mediated injury responsible for stunning occurs in initial moments of reperfusion • Antioxidant therapies alleviate stunning whether begun before ischemia or just prior to reperfusion • But ineffective when begun after reperfusion • None of the antioxidant therapies completely prevented myocardial stunning
  • 12. Calcium hypothesis • Transient Ca2+ overload activates Ca2+-dependent proteases which degrades and induces covalent modifications of myofilaments. • It results in ↓ responsiveness to Ca2+, manifested by a decrease in maximal force of contraction.
  • 13.
  • 15. • Term hibernation is borrowed from zoology and implies an adaptive reduction of energy expenditure through reduced activity in situation of reduced energy supply. • In CAD myocardial hibernation refers to adaptive reduction of myocardial contractile function in response to reduction of myocardial blood flow.
  • 16. • Diamond et al. in 1978 1st used the word hibernation in ischemic dog myocardium. • Its importance was recognized by Rahimtoola in early 1980s.
  • 17. Mechanisms of hibernation • Smart heart hypothesis : Myocardial metabolism and function are reduced to match concomitant reduction in coronary blood flow which prevents necrosis. • Repetitive stunning hypothesis: Repetitive episodes of ischemia results in sustained depression of contractile function.
  • 18. • Genomics of Survival Maintained viability in hibernation suggests possibility of genomic adaptation. Major survival genes (antiapoptotic, cytoprotective & growth-promoting genes) and their corresponding proteins are up regulated in hibernating myocardium.
  • 19.
  • 20. Natural history of hibernation
  • 21. Histological Features • Myolysis • Glycogen accumulation • Increased interstitial fibrosis
  • 22. Clinical Relevance • 20 to 50 % of pts with chronic ischemic LV dysfunction have significant amount of viable hibernating myocardium. • They improve with revascularization.
  • 23.
  • 24. ASSESSMENT OF MYOCARDIAL VIABILITY • ECG : gives little information. • Dobutamine stress echocardiography. • SPECT with thallium-201 or technetium-99 m. • PET • MRI
  • 25. Characteristics of dysfunctional but viable myocardium
  • 26. • ECG No clear correlation between Q waves on ECG and presence of viability. Pts with preserved QT dispersion are likely to have viable myocardium. Pts with high QT dispersion have predominantly non-viable scar tissue.
  • 27. Dobutamine Stress Echocardiography • Hypokinetic or akinetic regions improving during low dose dobutamine infusion (5–10 µg/kg/min) is indicative of viable tissue. • At higher doses (upto 40 µg/kg/min plus atropine) wall motion may improve or diminish, reflecting inducible ischemia. • Biphasic response is highly predictive of recovery of function after revascularization.
  • 28.
  • 29. Stress Echo Interpretation Interpretation Rest / Baseline Low dose stress Peak & post stress Normal Normal Normal Hyper dynamic Ischemic Normal Normal / severe ischemia – new RWMA Decreased Scar WMA No change No change Hibernating WMA Improved Worsens Stunned WMA Improved Improved
  • 30. • Advantage of Echo based techniques Safety , low cost , widespread availability of equipment . • Disadvantage Spatial resolution is relatively low. High interobserver variability. Diagnostic accuracy is reduced in pts with poor acoustic window.
  • 31. SPECT • Thallium-201 Early uptake is proportional to regional blood flow & delayed uptake indicates preserved Na+ K+ pump and an intact cell membrane. Defects on initial images that improve later are viable.
  • 32. • Technetium 99 lipophilic molecules and their intracellular retention requires intact mitochondrial function. Gating allow simultaneous assessment of myocardial perfusion & contractile function. • SPECT has higher sensitivity & lower specificity than techniques based on contractile reserve.
  • 33. PET • Glucose utilization is evaluated with FDG and regional perfusion assessed with N13-ammonia, rubidium-82, or O15- labeled water. • A normal perfusion and FDG uptake or reduced perfusion with enhanced FDG uptake indicates viable myocardium. • Concordant reduction in FDG uptake and myocardial perfusion is indicative of scar tissue. • PET is regarded as gold standard for viability assessment.
  • 34. Hibernation in LAD occlusion
  • 36.
  • 37. Magnetic resonance imaging • Three techniques are being used: 1.Resting MRI to measure end diastolic wall thickness. 2. Dobutamine MRI to evaluate contractile reserve 3. Contrast enhanced MRI to detect extent and transmurality of scar tissue.
  • 38. • Resting MRI End diastolic wall thickness < 6 mm represent transmural scar. • Dobutamine MRI Evaluate contractile reserve. Increased resolution of MRI avoid subjective variation of echo. Has sensitivity of 89% & specificity of 94% to predict improvement after revascularization.
  • 39. • Contrast enhanced MRI Allows precise detection of scar tissue. Extent & transmurality of scar can be assessed. Can detect subendocardial scar. Similar to FDG PET in detecting scar.
  • 40. Accuracy of non-invasive techniques to assess myocardial viability
  • 41. Impact of Revascularization on LV Function • Studies shows LV ejection fraction improves significantly (ie ≥ 5%) after revascularization in 60% of patients (range 38% to 88%). • To predict 5% improvement in LVEF, at least 25% of LV should be viable using DSE and ≈38% using conventional nuclear medicine and PET.
  • 42. • In dyskinetic and akinetic segments, absence of scar or a transmural extension of scar of <25% have PPV of 88% and NPV 89% for functional recovery.
  • 43. Treatment and Survival Rates • Meta-analysis that pooled data of 3,088 pts from 24 studies demonstrated improved survival after revascularization in pts with hibernation. • Revascularization resulted in 79.6% reduction in mortality (16% vs 3.2%) • In absence of hibernation, no significant difference in mortality with revascularization (7.7% vs 6.2%).
  • 44.
  • 45. Summary • Stunning and hibernation are 2 causes for LV dysfunction. • Both conditions imply presence of viable myocardium and are reversible.
  • 46. References • HURST’S THE HEART 13TH EDITION • BRAUNWALD’S HEART DISEASE NINTH EDITION • Medical and Cellular Implications of Stunning, Hibernation, and Preconditioning :Circulation. 1998;97:1848-1867 • Stunning, Hibernation and Assessment of Myocardial Viability : Circulation.2008;117:103-114 • Molecular and Cellular Mechanisms of Myocardial Stunning :PHYSIOLOGICAL REVIEWS Vol. 79, No. 2, April 1999
  • 47. • Hibernating Myocardium : PHYSIOLOGICAL REVIEWS Vol. 78, No. 4, October 1998 • Clinical assessment of myocardial hibernation Heart 2005;91;111-117